1.296 articles found

Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.

Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, Blond SY, Duka T, Rusnak M, Sidhu A.

ChemMedChem · 2006-02-01

DOI: 10.1002/cmdc.200500039PMID: 16892358

Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.

Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H.

Biochem Biophys Res Commun · 2006-01-25

DOI: 10.1016/j.bbrc.2006.01.057PMID: 16460685

Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT.

Neurobiol Dis · 2006-01-24

DOI: 10.1016/j.nbd.2005.12.003PMID: 16439141

Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.

Lehmensiek V, Tan EM, Liebau S, Lenk T, Zettlmeisl H, Schwarz J, Storch A.

Neurochem Int · 2006-01-06

DOI: 10.1016/j.neuint.2005.11.008PMID: 16406146

#alpha#--Synuclein aggregation and Parkinson's disease： Factors affecting the aggregation of #alpha#--Synuclein

Jin Ling, Yang Hui.

Sheng wu hua xue yu sheng wu wu li jin zhan · 2006-01-01

Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK.

J Neurosci · 2006-01-01

DOI: 10.1523/jneurosci.4308-05.2006PMID: 16399671

Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease.

Shavali S, Combs CK, Ebadi M.

Neurochem Res · 2006-01-01

DOI: 10.1007/s11064-005-9233-xPMID: 16475001

Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease.

Papapetropoulos S.

J Neuropsychiatry Clin Neurosci · 2006-01-01

DOI: 10.1176/jnp.2006.18.2.149PMID: 16720791

A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.

Giorgi FS, Bandettini di Poggio A, Battaglia G, Pellegrini A, Murri L, Ruggieri S, Paparelli A, Fornai F.

J Neural Transm Suppl · 2006-01-01

DOI: 10.1007/978-3-211-45295-0_17PMID: 17017516

Prolyl-isomerase Pin1 accumulates in lewy bodies of parkinson disease and facilitates formation of alpha-synuclein inclusions.

Ryo A, Togo T, Nakai T, Hirai A, Nishi M, Yamaguchi A, Suzuki K, Hirayasu Y, Kobayashi H, Perrem K, Liou YC, Aoki I.

J Biol Chem · 2005-12-19

DOI: 10.1074/jbc.m507026200PMID: 16365047

Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.

Braak H, de Vos RA, Bohl J, Del Tredici K.

Neurosci Lett · 2005-12-05

DOI: 10.1016/j.neulet.2005.11.012PMID: 16330147

Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease.

Klos KJ, Josephs KA, Parisi JE, Dickson DW.

Mov Disord · 2005-11-01

DOI: 10.1002/mds.20604PMID: 16035099